Expression of CD10, BCL-6 and MUM-1 Markers and Their Effects on Prognosis in Diffuse Large B Cell Lymphoma

INTRODUCTION: Immunohistochemistry may serve as a surrogate to define Diffuse large B-cell lymphoma (DLBCL) cases as germinal center B cell-like (GCB) or non-GCB subtypes and to provide prognostic information. In this study, we aimed to investigate the frequency and prognostic impact of CD10, B-cell lymphoma 2 and 6 (BCL2 and BCL6) and multiple myeloma oncogene 1 (MUM1) expressions in pathology sections of patients with DLBCL to determine the response of these subgroups to the rituximab including chemotherapy regimens.
METHODS: Patients were grouped into 2 regarding the chemotherapy regimens they were treated, as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or Rituximab-CHOP. The treatment response, follow-up periods and outcomes of patients were recorded. The immunohistochemical panel was stained in pathology sections for CD10, BCL6 and MUM1/IRF 4 biomarkers. The patients were subgrouped as GCB or ABC regarding the immunohistochemical panel.
RESULTS: Totally 81 patients, (39 male, 42 female) were included in the study. At the time of diagnosis, CD10 was positive in 31 patients (38.3%); BCL-6 in 53 patients (65.4%); MUM-1 was positive in 47 patients (58%) and BCL-2 was positive in 53 patients (65.4). With these results, 36 patients (44.4%) were in the GCB group and 45 patients (55.6%) were in the ABC group. No significant difference was found between the individual markers and subgroups in survival analyses.
DISCUSSION AND CONCLUSION: We did not determine any significant effect of CD10, BCL-6, MUM-1 or BCL-2 positivity or GCB and non-GCB groups in the survival of patients with DLBCL.

Diffüz Büyük B Hücreli Lenfoma’da CD10, BCL-6 and MUM-1 Markerlarýn Ekspresyonu ve Prognoz Üzerine Etkisi

GÝRÝÞ ve AMAÇ: Ýmmünohistokimya kullanýlarak, Diffüz büyük B hücreli lenfoma (DBBHL) vakalarý germinal merkez B hücresi benzeri (GCB) ve ABC grubu olmak üzere prognositk açýdan önemli olan alt tiplere ayrýlabilir. Biz bu çalýþmada DBBHL’li hastalarýn patoloji preparatlarýnda CD10, B hücreli lenfoma 2 ve 6 (BCL2 ve BCL6) ve multipl miyelom onkogen 1 (MUM1) markerlarýnýn sýklýðýný ve rituksimab içeren kemoterapi gruplarýndaki prognostik etkisini araþtýrmayý amaçladýk.
YÖNTEM ve GEREÇLER: Hastalar, kemoterapi rejimleri açýsýndan, siklofosfamid, doksorubisin, vinkristin ve prednizon (CHOP) veya Rituksimab-CHOP olarak 2'ye ayrýldý. Hastalarýn tedaviye yanýtý, takip süreleri ve tedavi sonuçlarý kaydedildi. Taný anýndaki patoloji preparatlarýndan CD10, BCL6 ve MUM1 / IRF 4 biyomarkerlarý için boyama yapýlarak hastalar immünohistokimyasal panel açýsýndan GCB veya ABC olarak alt gruplara ayrýldý.
BULGULAR: Toplam 81 hasta (39 erkek, 42 kadýn) çalýþmaya dahil edildi. Taný sýrasýnda 31 hastada (% 38,3) CD10; 53 hastada BCL-6 (% 65,4); MUM-1 47 hastada (% 58); BCL-2 53 hastada (65,4) pozitifti. Bu sonuçlarla 36 hasta (% 44.4) GCB grubu, 45 hasta (% 55.6) ABC grubu olarak tanýmlandý. Saðkalým analizinde gruplar ve biyomarkerlar arasýnda istatistiksel olarak anlamlý bir farklýlýk saptanmamýþtýr.
TARTIÞMA ve SONUÇ: DLBCL hastalarýnýn saðkalýmýnda CD10, BCL-6, MUM-1 veya BCL-2 pozitifliði veya GCB ve ABC gruplarýnýn anlamlý bir etkisi saptanmamýþtýr.